Brigham-led study estimates 1 in 7 Medicare beneficiaries with high body mass index may qualify for anti-obesity drug.
| Předmět: | |
|---|---|
| Zdroj: | Health Insurance Week; 9/9/2024, p227-227, 1p |
| Abstrakt: | The article highlights a Brigham-led study estimating that 1 in 7 Medicare beneficiaries with high body mass index (BMI) may qualify for semaglutide (Wegovy) under new Medicare coverage rules. Topics discussed include the impact of defining cardiovascular disease on eligibility, potential costs to Medicare, and the implications for public health and policy. |
| Databáze: | Complementary Index |
| Externí odkaz: |
|